Literature DB >> 8938131

Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo.

D R Borchelt1, G Thinakaran, C B Eckman, M K Lee, F Davenport, T Ratovitsky, C M Prada, G Kim, S Seekins, D Yager, H H Slunt, R Wang, M Seeger, A I Levey, S E Gandy, N G Copeland, N A Jenkins, D L Price, S G Younkin, S S Sisodia.   

Abstract

Mutations in the presenilin 1 (PS1) and presenilin 2 genes cosegregate with the majority of early-onset familial Alzheimer's disease (FAD) pedigrees. We now document that the Abeta1-42(43)/Abeta1-40 ratio in the conditioned media of independent N2a cell lines expressing three FAD-linked PS1 variants is uniformly elevated relative to cells expressing similar levels of wild-type PS1. Similarly, the Abeta1-42(43)/Abeta1-40 ratio is elevated in the brains of young transgenic animals coexpressing a chimeric amyloid precursor protein (APP) and an FAD-linked PS1 variant compared with brains of transgenic mice expressing APP alone or transgenic mice coexpressing wild-type human PS1 and APP. These studies provide compelling support for the view that one mechanism by which these mutant PS1 cause AD is by increasing the extracellular concentration of Abeta peptides terminating at 42(43), species that foster Abeta deposition.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8938131     DOI: 10.1016/s0896-6273(00)80230-5

Source DB:  PubMed          Journal:  Neuron        ISSN: 0896-6273            Impact factor:   17.173


  407 in total

Review 1.  The role of presenilins in Alzheimer's disease.

Authors:  G Thinakaran
Journal:  J Clin Invest       Date:  1999-11       Impact factor: 14.808

2.  Intraneuronal Abeta42 accumulation in human brain.

Authors:  G K Gouras; J Tsai; J Naslund; B Vincent; M Edgar; F Checler; J P Greenfield; V Haroutunian; J D Buxbaum; H Xu; P Greengard; N R Relkin
Journal:  Am J Pathol       Date:  2000-01       Impact factor: 4.307

Review 3.  The endosomal-lysosomal system of neurons in Alzheimer's disease pathogenesis: a review.

Authors:  R A Nixon; A M Cataldo; P M Mathews
Journal:  Neurochem Res       Date:  2000-10       Impact factor: 3.996

Review 4.  Metabolism of presenilins.

Authors:  G Thinakaran
Journal:  J Mol Neurosci       Date:  2001-10       Impact factor: 3.444

Review 5.  Spotlight on BACE: the secretases as targets for treatment in Alzheimer disease.

Authors:  C Dingwall
Journal:  J Clin Invest       Date:  2001-11       Impact factor: 14.808

6.  Amyloid angiopathy and variability in amyloid beta deposition is determined by mutation position in presenilin-1-linked Alzheimer's disease.

Authors:  D M Mann; S M Pickering-Brown; A Takeuchi; T Iwatsubo
Journal:  Am J Pathol       Date:  2001-06       Impact factor: 4.307

Review 7.  Cellular cofactors for amyloid beta-peptide-induced cell stress. Moving from cell culture to in vivo.

Authors:  S D Yan; A Roher; A M Schmidt; D M Stern
Journal:  Am J Pathol       Date:  1999-11       Impact factor: 4.307

8.  Alleles at the Nicastrin locus modify presenilin 1- deficiency phenotype.

Authors:  Richard Rozmahel; Howard T J Mount; Fusheng Chen; Van Nguyen; Jean Huang; Serap Erdebil; Jennifer Liauw; Gang Yu; Hiroshe Hasegawa; YongJun Gu; You-Qiang Song; Stephen D Schmidt; Ralph A Nixon; Paul M Mathews; Catherine Bergeron; Paul Fraser; David Westaway; Peter St George-Hyslop
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-18       Impact factor: 11.205

9.  Effects of the English (H6R) and Tottori (D7N) familial Alzheimer disease mutations on amyloid beta-protein assembly and toxicity.

Authors:  Kenjiro Ono; Margaret M Condron; David B Teplow
Journal:  J Biol Chem       Date:  2010-05-07       Impact factor: 5.157

10.  Aberrant amyloid precursor protein (APP) processing in hereditary forms of Alzheimer disease caused by APP familial Alzheimer disease mutations can be rescued by mutations in the APP GxxxG motif.

Authors:  Lisa-Marie Munter; Anne Botev; Luise Richter; Peter W Hildebrand; Veit Althoff; Christoph Weise; Daniela Kaden; Gerd Multhaup
Journal:  J Biol Chem       Date:  2010-05-07       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.